{"id":48162,"date":"2022-09-09T13:02:27","date_gmt":"2022-09-09T11:02:27","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/volastra-therapeutics-to-present-preclinical-data-from-kif18a-inhibitor-program-targeting-chromosomally-unstable-tumors-at-faseb-aneuploidy-conference\/"},"modified":"2022-09-09T13:02:27","modified_gmt":"2022-09-09T11:02:27","slug":"volastra-therapeutics-to-present-preclinical-data-from-kif18a-inhibitor-program-targeting-chromosomally-unstable-tumors-at-faseb-aneuploidy-conference","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/volastra-therapeutics-to-present-preclinical-data-from-kif18a-inhibitor-program-targeting-chromosomally-unstable-tumors-at-faseb-aneuploidy-conference\/","title":{"rendered":"Volastra Therapeutics to Present Preclinical Data from KIF18A Inhibitor Program Targeting Chromosomally Unstable Tumors at FASEB Aneuploidy Conference"},"content":{"rendered":"<div>\n<p class=\"bwalignc\">\n<i>Treatment with KIF18A inhibitor led to substantial, dose-dependent inhibition of tumor growth in multiple tumor models, with no effect on normal cells<\/i>\n<\/p>\n<p class=\"bwalignc\">\n<i>KIF18A inhibitor on track to enter the clinic in 2H 2023<\/i>\n<\/p>\n<p>NEW YORK&#8211;(BUSINESS WIRE)&#8211;<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.volastratx.com%2F&amp;esheet=52879355&amp;newsitemid=20220909005089&amp;lan=en-US&amp;anchor=Volastra+Therapeutics&amp;index=1&amp;md5=af9396eb1935c6ff49e634d0b3a74413\" rel=\"nofollow noopener\" shape=\"rect\">Volastra Therapeutics<\/a>, an oncology company focused on exploiting chromosomal instability (CIN), today announced new data from its lead program, a KIF18A inhibitor, validating its therapeutic approach of synthetic lethality to induce tumor cell death. The data will be presented at the 2022 Consequences of Aneuploidy Conference, organized by the Federation of American Societies for Experimental Biology (FASEB), which takes place September 11 \u2013 16, 2022, in Southbridge, Mass.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220909005089\/en\/1566543\/5\/FinalVolastraLogo2_RGB_Foundry._Sterling_Light_copy_%282%29.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220909005089\/en\/1566543\/21\/FinalVolastraLogo2_RGB_Foundry._Sterling_Light_copy_%282%29.jpg\"><\/a><\/p>\n<p>\nKIF18A is a mitotic kinesin that regulates chromosome alignment during cell division. Leveraging its proprietary CINtech platform, Volastra discovered that CIN-high cancer cells are more dependent on chromosome alignment machinery like KIF18A and are thus more vulnerable to KIF18A inhibition than normal cells.\n<\/p>\n<p>\n\u201c<!-- no quote -->Despite the prevalence of chromosomal instability across many tumor types, it has not been fully exploited therapeutically. We are excited to share new preclinical data from our KIF18A inhibitor program showing the ability of this compound to inhibit tumor growth in multiple different models of CIN-high cancer, while leaving normal proliferating cells intact,\u201d said Michael Su, Ph.D., Chief Scientific Officer at Volastra. \u201c<!-- no quote -->These findings set our KIF18A inhibitor apart from traditional chemotherapies, which can have a detrimental impact on healthy cells. We anticipate initiating a Phase 1 study for this potential best-in-class KIF18A inhibitor in the second half of 2023.\u201d\n<\/p>\n<p>\nThe FASEB keynote speaker, Professor David Pellman, M.D., of the Dana-Farber Cancer Institute and Volastra Scientific Advisory Board member, states, \u201c<!-- no quote -->The therapeutic potential of targeting chromosomal instability is increasingly compelling. These new data from Volastra\u2019s KIF18A inhibitor further support the promise of developing new and better cancer therapies through a deep understanding of this vulnerability.\u201d\n<\/p>\n<p>\nDetails of Volastra\u2019s oral data presentation at the Consequences of Aneuploidy Conference are as follows:\n<\/p>\n<p class=\"bwmarginl1\">\n<b>Title<\/b>: \u201c<!-- no quote -->Discovery and Development of KIF18A Inhibitors for the Treatment of Chromosomally Unstable Tumors\u201d<br \/>\n<br \/><b>Session<\/b>: Aneuploidy and Tumor Therapy<br \/>\n<br \/><b>Date and Time<\/b>: Tuesday, September 13, 2022; 2:20 p.m. ET<br \/>\n<br \/><b>Presenter<\/b>: Christina Eng, Ph.D., Vice President, Head of Biology, Volastra Therapeutics\n<\/p>\n<p>\n<b>About Volastra\u2019s CINtech Platform<\/b>\n<\/p>\n<p>\nVolastra\u2019s CINtech platform harnesses a deep biological understanding of chromosomal instability (CIN) as cancer\u2019s most targetable vulnerability to develop promising therapies for patients. CINtech integrates proprietary imaging technologies, model cell line systems and computational analytics to drive a broad and differentiated pipeline. Volastra recently announced a multi-year, up to $1.1 billion, drug discovery collaboration with Bristol Myers Squibb leveraging Volastra\u2019s proprietary CINtech platform to identify CIN-related targets. In addition, Volastra has a partnership with Microsoft to develop AI technologies for the interrogation of CIN.\n<\/p>\n<p>\n<b>About Volastra Therapeutics, Inc.<\/b>\n<\/p>\n<p>\nVolastra Therapeutics is a New York-based drug discovery and therapeutics company pioneering novel approaches to treating cancer by exploiting chromosomal instability (CIN), cancer\u2019s most targetable vulnerability. Founded by Lewis Cantley, Ph.D., Olivier Elemento, Ph.D., and Samuel Bakhoum, M.D., Ph.D., Volastra is rapidly developing and implementing new methods to exploit this vulnerability. Leveraging its proprietary CINtech platform, the company is advancing a novel synthetic lethal and immune activating pipeline. Volastra\u2019s lead program targets KIF18A, a mitotic kinesin, with a first-in-human study anticipated to start in 2023.\n<\/p>\n<p>\nFor more information, please visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.volastratx.com%2F&amp;esheet=52879355&amp;newsitemid=20220909005089&amp;lan=en-US&amp;anchor=volastratx.com&amp;index=2&amp;md5=035b7fd25f882d3b97046eb6a42ccba8\" rel=\"nofollow noopener\" shape=\"rect\">volastratx.com<\/a>.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>Media<\/b>\n<\/p>\n<p>\nLisa Qu<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#105;&#108;to&#x3a;&#x4c;&#x51;&#117;&#64;t&#x65;&#x6e;&#x62;&#114;&#105;d&#x67;&#x65;&#x63;&#111;&#109;m&#x75;&#x6e;&#x69;&#99;&#97;ti&#x6f;&#x6e;&#x73;&#46;co&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#76;Q&#x75;&#64;&#x74;e&#x6e;b&#x72;&#105;&#x64;&#103;&#x65;&#99;&#x6f;&#109;m&#117;n&#x69;c&#x61;t&#x69;&#111;&#x6e;&#115;&#x2e;&#99;&#x6f;&#109;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Treatment with KIF18A inhibitor led to substantial, dose-dependent inhibition of tumor growth in multiple tumor models, with no effect on normal cells KIF18A inhibitor on track to enter the clinic in 2H 2023 NEW YORK&#8211;(BUSINESS WIRE)&#8211;Volastra Therapeutics, an oncology company focused on exploiting chromosomal instability (CIN), today announced new data from its lead program, a &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/volastra-therapeutics-to-present-preclinical-data-from-kif18a-inhibitor-program-targeting-chromosomally-unstable-tumors-at-faseb-aneuploidy-conference\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-48162","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Volastra Therapeutics to Present Preclinical Data from KIF18A Inhibitor Program Targeting Chromosomally Unstable Tumors at FASEB Aneuploidy Conference - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/volastra-therapeutics-to-present-preclinical-data-from-kif18a-inhibitor-program-targeting-chromosomally-unstable-tumors-at-faseb-aneuploidy-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Volastra Therapeutics to Present Preclinical Data from KIF18A Inhibitor Program Targeting Chromosomally Unstable Tumors at FASEB Aneuploidy Conference - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Treatment with KIF18A inhibitor led to substantial, dose-dependent inhibition of tumor growth in multiple tumor models, with no effect on normal cells KIF18A inhibitor on track to enter the clinic in 2H 2023 NEW YORK&#8211;(BUSINESS WIRE)&#8211;Volastra Therapeutics, an oncology company focused on exploiting chromosomal instability (CIN), today announced new data from its lead program, a ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/volastra-therapeutics-to-present-preclinical-data-from-kif18a-inhibitor-program-targeting-chromosomally-unstable-tumors-at-faseb-aneuploidy-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-09T11:02:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220909005089\/en\/1566543\/21\/FinalVolastraLogo2_RGB_Foundry._Sterling_Light_copy_%282%29.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/volastra-therapeutics-to-present-preclinical-data-from-kif18a-inhibitor-program-targeting-chromosomally-unstable-tumors-at-faseb-aneuploidy-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/volastra-therapeutics-to-present-preclinical-data-from-kif18a-inhibitor-program-targeting-chromosomally-unstable-tumors-at-faseb-aneuploidy-conference\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Volastra Therapeutics to Present Preclinical Data from KIF18A Inhibitor Program Targeting Chromosomally Unstable Tumors at FASEB Aneuploidy Conference\",\"datePublished\":\"2022-09-09T11:02:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/volastra-therapeutics-to-present-preclinical-data-from-kif18a-inhibitor-program-targeting-chromosomally-unstable-tumors-at-faseb-aneuploidy-conference\\\/\"},\"wordCount\":583,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/volastra-therapeutics-to-present-preclinical-data-from-kif18a-inhibitor-program-targeting-chromosomally-unstable-tumors-at-faseb-aneuploidy-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220909005089\\\/en\\\/1566543\\\/21\\\/FinalVolastraLogo2_RGB_Foundry._Sterling_Light_copy_%282%29.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/volastra-therapeutics-to-present-preclinical-data-from-kif18a-inhibitor-program-targeting-chromosomally-unstable-tumors-at-faseb-aneuploidy-conference\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/volastra-therapeutics-to-present-preclinical-data-from-kif18a-inhibitor-program-targeting-chromosomally-unstable-tumors-at-faseb-aneuploidy-conference\\\/\",\"name\":\"Volastra Therapeutics to Present Preclinical Data from KIF18A Inhibitor Program Targeting Chromosomally Unstable Tumors at FASEB Aneuploidy Conference - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/volastra-therapeutics-to-present-preclinical-data-from-kif18a-inhibitor-program-targeting-chromosomally-unstable-tumors-at-faseb-aneuploidy-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/volastra-therapeutics-to-present-preclinical-data-from-kif18a-inhibitor-program-targeting-chromosomally-unstable-tumors-at-faseb-aneuploidy-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220909005089\\\/en\\\/1566543\\\/21\\\/FinalVolastraLogo2_RGB_Foundry._Sterling_Light_copy_%282%29.jpg\",\"datePublished\":\"2022-09-09T11:02:27+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/volastra-therapeutics-to-present-preclinical-data-from-kif18a-inhibitor-program-targeting-chromosomally-unstable-tumors-at-faseb-aneuploidy-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/volastra-therapeutics-to-present-preclinical-data-from-kif18a-inhibitor-program-targeting-chromosomally-unstable-tumors-at-faseb-aneuploidy-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/volastra-therapeutics-to-present-preclinical-data-from-kif18a-inhibitor-program-targeting-chromosomally-unstable-tumors-at-faseb-aneuploidy-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220909005089\\\/en\\\/1566543\\\/21\\\/FinalVolastraLogo2_RGB_Foundry._Sterling_Light_copy_%282%29.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220909005089\\\/en\\\/1566543\\\/21\\\/FinalVolastraLogo2_RGB_Foundry._Sterling_Light_copy_%282%29.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/volastra-therapeutics-to-present-preclinical-data-from-kif18a-inhibitor-program-targeting-chromosomally-unstable-tumors-at-faseb-aneuploidy-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Volastra Therapeutics to Present Preclinical Data from KIF18A Inhibitor Program Targeting Chromosomally Unstable Tumors at FASEB Aneuploidy Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Volastra Therapeutics to Present Preclinical Data from KIF18A Inhibitor Program Targeting Chromosomally Unstable Tumors at FASEB Aneuploidy Conference - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/volastra-therapeutics-to-present-preclinical-data-from-kif18a-inhibitor-program-targeting-chromosomally-unstable-tumors-at-faseb-aneuploidy-conference\/","og_locale":"en_US","og_type":"article","og_title":"Volastra Therapeutics to Present Preclinical Data from KIF18A Inhibitor Program Targeting Chromosomally Unstable Tumors at FASEB Aneuploidy Conference - Pharma Trend","og_description":"Treatment with KIF18A inhibitor led to substantial, dose-dependent inhibition of tumor growth in multiple tumor models, with no effect on normal cells KIF18A inhibitor on track to enter the clinic in 2H 2023 NEW YORK&#8211;(BUSINESS WIRE)&#8211;Volastra Therapeutics, an oncology company focused on exploiting chromosomal instability (CIN), today announced new data from its lead program, a ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/volastra-therapeutics-to-present-preclinical-data-from-kif18a-inhibitor-program-targeting-chromosomally-unstable-tumors-at-faseb-aneuploidy-conference\/","og_site_name":"Pharma Trend","article_published_time":"2022-09-09T11:02:27+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220909005089\/en\/1566543\/21\/FinalVolastraLogo2_RGB_Foundry._Sterling_Light_copy_%282%29.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/volastra-therapeutics-to-present-preclinical-data-from-kif18a-inhibitor-program-targeting-chromosomally-unstable-tumors-at-faseb-aneuploidy-conference\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/volastra-therapeutics-to-present-preclinical-data-from-kif18a-inhibitor-program-targeting-chromosomally-unstable-tumors-at-faseb-aneuploidy-conference\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Volastra Therapeutics to Present Preclinical Data from KIF18A Inhibitor Program Targeting Chromosomally Unstable Tumors at FASEB Aneuploidy Conference","datePublished":"2022-09-09T11:02:27+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/volastra-therapeutics-to-present-preclinical-data-from-kif18a-inhibitor-program-targeting-chromosomally-unstable-tumors-at-faseb-aneuploidy-conference\/"},"wordCount":583,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/volastra-therapeutics-to-present-preclinical-data-from-kif18a-inhibitor-program-targeting-chromosomally-unstable-tumors-at-faseb-aneuploidy-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220909005089\/en\/1566543\/21\/FinalVolastraLogo2_RGB_Foundry._Sterling_Light_copy_%282%29.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/volastra-therapeutics-to-present-preclinical-data-from-kif18a-inhibitor-program-targeting-chromosomally-unstable-tumors-at-faseb-aneuploidy-conference\/","url":"https:\/\/pharma-trend.com\/en\/volastra-therapeutics-to-present-preclinical-data-from-kif18a-inhibitor-program-targeting-chromosomally-unstable-tumors-at-faseb-aneuploidy-conference\/","name":"Volastra Therapeutics to Present Preclinical Data from KIF18A Inhibitor Program Targeting Chromosomally Unstable Tumors at FASEB Aneuploidy Conference - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/volastra-therapeutics-to-present-preclinical-data-from-kif18a-inhibitor-program-targeting-chromosomally-unstable-tumors-at-faseb-aneuploidy-conference\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/volastra-therapeutics-to-present-preclinical-data-from-kif18a-inhibitor-program-targeting-chromosomally-unstable-tumors-at-faseb-aneuploidy-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220909005089\/en\/1566543\/21\/FinalVolastraLogo2_RGB_Foundry._Sterling_Light_copy_%282%29.jpg","datePublished":"2022-09-09T11:02:27+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/volastra-therapeutics-to-present-preclinical-data-from-kif18a-inhibitor-program-targeting-chromosomally-unstable-tumors-at-faseb-aneuploidy-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/volastra-therapeutics-to-present-preclinical-data-from-kif18a-inhibitor-program-targeting-chromosomally-unstable-tumors-at-faseb-aneuploidy-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/volastra-therapeutics-to-present-preclinical-data-from-kif18a-inhibitor-program-targeting-chromosomally-unstable-tumors-at-faseb-aneuploidy-conference\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220909005089\/en\/1566543\/21\/FinalVolastraLogo2_RGB_Foundry._Sterling_Light_copy_%282%29.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220909005089\/en\/1566543\/21\/FinalVolastraLogo2_RGB_Foundry._Sterling_Light_copy_%282%29.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/volastra-therapeutics-to-present-preclinical-data-from-kif18a-inhibitor-program-targeting-chromosomally-unstable-tumors-at-faseb-aneuploidy-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Volastra Therapeutics to Present Preclinical Data from KIF18A Inhibitor Program Targeting Chromosomally Unstable Tumors at FASEB Aneuploidy Conference"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48162","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=48162"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48162\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=48162"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=48162"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=48162"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}